UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 000-50644 Cutera, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0492262 (State or other j ...

The Zacks Laser Systems and Components industry is suffering from challenging macroeconomic conditions globally, weak economic conditions in Europe and a sluggish economic environment in China. Continued economic uncertainty with low PMI numbers in Europe, North America and Japan is impacting industrial demand and capital investments. However, industry participants like MicroVision (MVIS) , Cutera (CUTR) and IRIDEX Corporation (IRIX) benefit from upbeat demand from electric vehicles, electronics, semiconduc ...

AviClear® is now available in select practices in the United Kingdom, Europe, and Australia (Photo: Cutera)AviClear® is now available in select practices in the United Kingdom, Europe, and Australia (Photo: Cutera)BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced the international limited commercial release of AviClear, the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. A ...

So just one more comment on this front. Q4 as well as Q1 of next year, we'll have the similar dynamics. But after that, we do believe that we're going to be able to shift into a different load with respect to working capital, where we're able to start working down, AviClear as well as the core inventory positions and will be caught up on our payables. So that's going to be -- that plus the new business model that we have for AviClear should result in more favorable cash dynamics Q2 onward of next year. Oper ...

Company Participants Stuart Drummond - Interim Chief Financial Officer Greg Barker - Vice President of Financial Planning and Investor Relations George Sellers - Stephens Inc. Cutera, Inc. (NASDAQ:CUTR) Q2 2023 Earnings Call Transcript August 8, 2023 4:30 PM ET Sheila Hopkins - Former Interim Chief Executive Officer Taylor Harris - Chief Executive Officer Conference Call Participants Jon Block - Stifel Anthony Vendetti - Maxim Group Operator The discussion today includes forward-looking statements. These fo ...

CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share, per share data and par value) (Unaudited) | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|---------------|-------|-------------------| | Assets | | June 30, 2023 | | December 31, 2022 | | Current assets: | | | | | | Cash and cash equivalents | $ | 180,654 | $ | 145,924 | | ...

Cutera, Inc. (NASDAQ:CUTR) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Sheila Hopkins - Interim Chief Executive Officer Conference Call Participants Jon Block - Stifel Margaret Kaczor - William Blair Operator The discussion today includes forward-looking statements. These forward-looking statements reflect management's current forecast or expectation of current aspects of the company's future business including, but not limited to any financial guidance provided for modeling purposes. Forward-lo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 000-50644 Cutera, Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |---------------------------------------------------------|---------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents FORM 10-K Acne – The Company's acne solution, AviClear, is a prescription-free, drug-free laser treatment that is safe for all skin types and tones and FDA-cleared for the treatment of mild to severe acne. The device can provide lasting clearance without significant side effects in three 30-minute treatment sessions. Acne forms when sebum, the oily substance on skin, combines with dead skin cells and clogs pores. The C ...

Non-GAAP sales and marketing expenses for the fourth quarter of 2022 were $26 million compared to $22.3 million for the same period last year driven by continued expansion in our sales force, higher commissions and increased travel. Non-GAAP R&D expenses for the fourth quarter of 2022 were $5.5 million compared to $5.6 million for the same period last year. Non-GAAP G&A expenses for the fourth quarter of 2022 were $8.3 million compared to $6.6 million in the same period last year driven by expansion in our ...